The evolution of leukaemia from pre-leukaemic and leukaemic stem cells.
acute Leukaemia
cancer
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
30
1
2021
medline:
12
10
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
Haematopoietic stem and progenitor cells (HSPCs) are defined as unspecialized cells that give rise to more differentiated cells. In a similar way, leukaemic stem and progenitor cells (LSPCs) are defined as unspecialized leukaemic cells, which can give rise to more differentiated cells. Leukaemic cells carry leukaemic mutations/variants and have clear differentiation abnormalities. Pre-leukaemic HSPCs (PreL-HSPCs) carry pre-leukaemic mutations/variants (pLMs) and are capable of producing mature functional cells, which will carry the same variants. Under the roof of LSPCs, one can find a broad range of cell types genetic and disease phenotypes. Present-day knowledge suggests that this phenotypic heterogeneity is the result of interactions between the cell of origin, the genetic background and the microenvironment background. The combination of these attributes will define the LSPC phenotype, frequency, differentiation capacity and evolutionary trajectory. Importantly, as LSPCs are leukaemia-initiating cells that sustain clinical remission and are the source of relapse, an improved understanding of LSPCs phenotype would offer better clinical opportunities for the treatment and hopefully prevention of human leukaemia. The current review will focus on LSPCs attributes in the context of human haematologic malignancies.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
636-649Informations de copyright
© 2021 The Association for the Publication of the Journal of Internal Medicine.
Références
Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651-60.
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
Singh SK et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
Carrelha J et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature 2018; 554: 106-11.
Arends CM et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia 2018; 32: 1908-19.
Shlush LI et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-33.
Bogani C et al. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica 2007; 92: 258-9.
Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014; 111: 2548-53.
Abelson S et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 2018; 559: 400-4.
Shlush LI et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 2017; 547: 104-8.
Goardon N et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138-52.
Mossner M et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 2016; 128: 1246-59.
Nilsson L et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 2012-21.
Stevens BM et al. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nat Commun 2018; 9: 3694.
Chen J et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med 2019; 25: 103-10.
Rampal R et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A 2014; 111: E5401-5410.
Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000; 97: 7521-6.
Krivtsov AV et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013; 27: 852-60.
Damm F et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014; 4: 1088-101.
Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35: 418-29.
Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2016; 91: 1645-66.
Malouf C, Ottersbach K. Molecular processes involved in B cell acute lymphoblastic leukaemia. Cell Mol Life Sci 2018; 75: 417-46.
Shah S et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 2013; 45: 1226-31.
Hong D et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-9.
Kong Y et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008; 22: 1207-13.
Buchner M, Swaminathan S, Chen Z, Muschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunol Rev 2015; 263: 192-209.
Cobaleda C et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95: 1007-13.
Castor A et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630-7.
Kim T et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 2017; 129: 38-47.
Giustacchini A et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med 2017; 23: 692-702.
Jamieson CH et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-67.
Minami Y et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A 2008; 105: 17967-72.
Swaminathan S et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol 2015; 16: 766-74.
Puente XS et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-5.
Polak P et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 2015; 518: 360-4.
Li MM et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017; 19: 4-23.
Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24.
Lee-Six H et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 2018; 561: 473-8.
Fan J, Li L, Small D, Rassool F. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood 2010; 116: 5298-305.
Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-21.
Mansour MR et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014; 346: 1373-7.
Welch JS et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-78.
Stephens PJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
Notta F et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-7.
Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci U S A 2014; 111: 17947-52.
Shlush LI et al. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. Blood 2012; 120: 603-12.
Landau DA et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-26.
Gaiti F et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature 2019; 569: 576-80.
Almeida M et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282: 27285-97.
Tanaka T et al. Plasma proteomic signature of age in healthy humans. Aging Cell 2018; 17: e12799.
Verovskaya EV, Dellorusso PV, Passegue E. Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation. Trends Mol Med 2019; 25: 494-515.
Moorman AV, Roman E, Cartwright RA, Morgan GJ. Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia. Br J Cancer 2002; 86: 1061-3.
Walkley CR et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007; 129: 1097-110.
Raaijmakers MH et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-7.
Kode A et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 2014; 506: 240-4.
Dong L et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 2016; 539: 304-8.
Beerman I, Seita J, Inlay MA, Weissman IL, Rossi DJ. Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 2014; 15: 37-50.
Zambetti NA et al. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 2016; 19: 613-27.
Jaiswal S et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377: 111-21.
Fuster JJ et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017; 355: 842-7.
Meisel M et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 2018; 557: 580-4.
Welner RS et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 2015; 27: 671-81.
Colmone A et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322: 1861-5.
Duan CW et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell 2014; 25: 778-93.
Schepers K et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013; 13: 285-99.
Duarte D et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 2018; 22: 64-77 e66.
Arranz L et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 2014; 512: 78-81.
Corrado C et al. Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor. J Cell Mol Med 2016; 20: 1829-39.
Ye H et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 2016; 19: 23-37.
Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-43.
Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-33.
Collins CT, Hess JL. Deregulation of the HOXA9/MEIS1 axis in acute leukemia. Curr Opin Hematol 2016; 23: 354-61.
Park SM et al. IKZF2 drives leukemia stem cell self-renewal and inhibits myeloid differentiation. Cell Stem Cell 2019; 24: 153-165 e157.
Zhang Y et al. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/beta-catenin signaling pathway. Blood 2013; 121: 4906-16.
Kikushige Y et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 2015; 17: 341-52.
Kaufmann KB et al. A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency. Blood 2019; 133: 2198-211.
van Rhenen A et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110: 2659-66.
Jordan CT et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777-84.
Lapidot T et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
Majeti R et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-99.
Hosen N et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 2007; 104: 11008-13.
Pabst C et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood 2016; 127: 2018-27.
Zeijlemaker W et al. CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia 2019; 33: 1102-12.
Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304: 2706-15.
Eppert K et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-93.
Ng SW et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 2016; 540: 433-7.
Bahr C et al. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature 2018; 553: 515-20.
Groschel S et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014; 157: 369-81.
Reizel Y et al. Gender-specific postnatal demethylation and establishment of epigenetic memory. Genes Dev 2015; 29: 923-33.
Guryanova OA et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med 2016; 22: 1488-95.
Funayama K, Murai F, Shimane M, Nomura H, Asano S. Adhesion-induced drug resistance in leukemia stem cells. Pharmacology 2010; 86: 79-84.
Walter D et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature 2015; 520: 549-52.
Ishikawa F et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-21.
Sukhai MA et al. Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest 2013; 123: 315-28.
Li Y et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010; 16: 214-8.
van Galen P et al. Integrated stress response activity marks stem cells in normal hematopoiesis and leukemia. Cell Rep 2018; 25: 1109-1117 e1105.
Verhagen H et al. IGFBP7 induces differentiation and loss of survival of human acute myeloid leukemia stem cells without affecting normal hematopoiesis. Cell Rep 2018; 25: 3021-3035 e3025.
Patten DK et al. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat Med 2018; 24: 1469-80.
Pollyea DA et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med 2018; 24: 1859-66.
Cole A et al. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2015; 27: 864-76.
Kuntz EM et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med 2017; 23: 1234-40.
Lagadinou ED et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329-41.
Skrtic M et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2011; 20: 674-88.
Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell 2011; 9: 298-310.
Schimmer AD. Mitochondrial shapeshifting impacts AML stemness and differentiation. Cell Stem Cell 2018; 23: 3-4.
Jones CL et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 2018; 34: 724-740.e724.
Jones CL et al. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood 2019; 134: 389-94.
Raffel S et al. BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 2017; 551: 384-8.
Sykes DB et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 2016; 167: 171-186.e115.